BIB ETF Research - Ultra Nasdaq Biotechnology

Ultra Nasdaq Biotechnology (bib)

Last Updated by WikiWealth | Update This Page Now

►Summary | Add New ETF | Feedback

Short Term Rating Stock Ratings Help

Asset Allocation (% of Port)

US Stocks
Non-US Stocks

Geographic Allocation (% of Port)

North America
South America
Australia + Pacific Islands
Long Term Rating Stock Ratings Help


SWOT Statistics

Strengths + Opportunities = 101

Threats + Weaknesses = 69

When strengths & opportunities substantially exceed threats & weaknesses an investment in the bib ETF has great long term potential.

ETF Description Update

Ultra Nasdaq Biotechnology (BIB) Description: BIB is an exchange trading fund (ETF), which is a security that tracks a basket of assets, but trades like a stock. BIB exchange trading fund (ETF) tracks the Biotech (200%); this equity index contains nsdq listed companies classified as either biotechnology or pharmaceuticals companies. Ultra Nasdaq Biotechnology (BIB) falls under the Leveraged Equities category. BIB's dividend yield is roughly 0%, it has an expense ratio of 0.95%, and is in the equity ETF asset class. Ultra Nasdaq Biotechnology (BIB) focuses its investments in the U.S. region of the world. BIB has an ETF leverage of two times (2x) and BIB's performance is meant to match its benchmark. The BIB ETF belongs to the Health & Biotech sector. An investor can find BIB's top holdings, fundamental analysis, and fund ratings on the left side of the screen. The right side features BIB's technical analysis chart and long term fund potential. Long term and short term buy ratings indicate our highest possible valuation rating. Click here for additional information on ProShares ETF funds or see the ETF research & analysis home page to start.

Portfolio Strategy Update

Be the first to explain Ultra Nasdaq Biotechnology (BIB)'s strategy.

Performance Analysis Update